It's good we have reached the stage where CZM is actively...

It's good we have reached the stage where CZM is actively promoting and demonstrating CONVIVO along its KINEVO product.

What bothers me with OIL's FY18 financials is the administration and R&D expense lines. They eat up all of the cash generated by revenue and yet it's hard to see what kind of return these expenses bring.

How much more R&D is required?

How come OIL is spending that much money on marketing? Carl Zeiss has already dedicated 60 sales staff to promote and sell the microscopes! I take it that marketing spend may relate to ViewnVivo, but we haven't seen much return judging by slow sales.

I'd like to see the costs reduced substantially in FY19. I expect the management to preserve cash, stop asking shareholders for more money and work out a decent strategy around ViewnVivo!